Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAL401 in advanced NSCLC
NCT02875340Phase 2Completed
- Sponsor
- ValiSeek Limited
- Start
- Oct 2016
- Primary completion
- Sep 2017
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of risperidone formulation in rumenic acid in lung adenocarcinoma (LUAD), sponsored by ValiSeek Limited. Started Oct 2016; status: completed.
02
Drugs
risperidone formulation in rumenic acid
03
Conditions
lung adenocarcinoma (LUAD)
Beyond the preview
Go deeper on NCT02875340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02875340.